Have a personal or library account? Click to login
Interleukin-18 Promoter Gene Polymorphisms are not Associated with Myocardial Infarction in Type 2 Diabetes in Slovenia Cover

Interleukin-18 Promoter Gene Polymorphisms are not Associated with Myocardial Infarction in Type 2 Diabetes in Slovenia

By: S Kariž and  D Petrovič  
Open Access
|Jul 2011

References

  1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999; 340(2): 115-126.10.1056/NEJM1999011434002079887164
  2. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia. 1998; 41(10): 1241-1248.10.1007/s0012500510589794114
  3. Libby P. Inflammation in atherosclerosis. Nature. 2002; 420(6917):868-874.10.1038/nature0132312490960
  4. Haffner SM. Coronary heart disease in patients with diabetes. N Engl J Med. 2000; 342(14): 1040-1042.10.1056/NEJM20000406342140810749967
  5. Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med. 2002; 195(2): 245-257.10.1084/jem.20011022219360711805151
  6. Mallat Z, Corbaz A, Scoazec A, Besnard S, Leseche G, Chvatchko Y, Tedgui A. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation. 2001; 104(104): 1598-1603.10.1161/hc3901.09672111581135
  7. Whitman SC, Ravisankar P, Daugherty A. Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-γ. Circ Res. 2002; 90(2): e34-e38.10.1161/hh0202.10529211834721
  8. Mallat Z, Corbaz A, Scoazec A, Graber P, Alouani S, Esposito B, Humbert Y, Chvatchko Y, Tedgui A. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res. 2001; 89(7): e41-e45.10.1161/hh1901.09873511577031
  9. Mallat Z, Henry P, Fressonnet R, Alouani S, Scoazec A, Beaufils P, Chvatchko Y, Tedgui A. Increased plasma concentrations of interleukin-18 in acute coronary syndromes. Heart. 2002; 88(5): 467-469.10.1136/heart.88.5.467176743112381634
  10. Esposito K, Nappo F, Giugliano D, Di Palo C, Ciotola M, Barbieri M, Paolisso G, Giugliano D. Cyokine milieu tends toward inflammation in type 2 diabetes. Diabetes Care. 2003; 26(5): 1647.10.2337/diacare.26.5.164712716849
  11. Aso Y, Okumura KI, Takebayashi K, Wakabayashi S, Inukai T. Relationships of plasma interleukin-18 concentrations to hyperhomocysteinemia and carotid intima-media wall thickness in patients with type 2 diabetes. Diabetes Care. 2003; 26(9): 2622-2627.10.2337/diacare.26.9.2622
  12. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002; 106:(16): 2067-2072.10.1161/01.CIR.0000034509.14906.AE
  13. Giedraitis V, He B, Huang WX, Hillert J. Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J Neuroimmunol. 2001; 112(1-2): 146-152.10.1016/S0165-5728(00)00407-0
  14. Tiret L, Godefroy T, Lubos E, Nicaud V, Tregouet DA, Barbaux S, Schnabel R, Bickel C, Espinola-Klein C, Poirier O, Perret C, Munzel T, Rupprecht HJ, Lackner K, Cambien F, Blankenberg S, for the AtheroGene Investigators. Genetic analysis of the interleukin-18 aystem highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation. 2005; 112(5): 643-650.10.1161/CIRCULATIONAHA.104.519702
  15. Hernesniemi JA, Karhunen PJ, Rontu R, Ilveskoski E, Kajander O, Goebeler S, Viiri LE, Pessi T, Hurme M, Lehtimäki T. Interleukin-18 promoter polymorphism associates with the occurrence of sudden cardiac death among Caucasian males: The Helsinki Sudden Death Study. Atherosclerosis. 2008; 196(2): 643-649.10.1016/j.atherosclerosis.2007.07.018
  16. Liu W, Tang Q, Jiang H, Ding X, Liu Y, Zhu R, Tang Y, Li B, Wei M. Promoter polymorphism of inerleukin-18 in angiographically proven coronary artery disease. Angiology. 2009; 60(2): 180-185.10.1177/0003319708319939
  17. Kretowski A, Mironczuk K, Karpinska A, Bojaryn U, Kinalski M, Puchalski Z, Kinalska I. Interleukin-18 promoter polymorphisms in type 1 diabetes. Diabetes. 2002; 51(11): 3347-3349.10.2337/diabetes.51.11.3347
  18. Bossu P, Ciaramella A, Moro ML, Bellincampi L, Bernardini S, Federici G, Trequattrini A, Macciardi F, Spoletini I, Di Iulio F, Caltagirone C, Spalletta G. Interleukin 18 gene polymorphisms predict risk and outcome of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2007; 78(8): 807-811.10.1136/jnnp.2006.103242
  19. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003; 26(Suppl 1): S5-S20.10.2337/diacare.26.2007.S5
  20. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000; 36(3): 959-969.10.1016/S0735-1097(00)00804-4
  21. Szeszko JS, Howson JM, Cooper JD, Walker NM, Twells RC, Stevens HE, Nutland SL, Todd JA. Analysis of polymorphisms of the interleukin-18 gene in type 1 diabetes and Hardy-Weinberg equilibrium testing. Diabetes. 2006; 55(2): 559-562.10.2337/diabetes.55.02.06.db05-082616443795
  22. Ford E. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care. 1999; 22(12): 1971-1977.
  23. Schulze M, Rifai N, Rimm E, Stampfer M, Li T, Hu F. C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care. 2004; 27(4): 889-894.10.2337/diacare.27.4.88915047644
  24. Soinio M, Marniemi J, Laakso M, Lehto S, Rönnemaa T. High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: a 7-year follow-up study. Diabetes Care. 2006; 29(2): 329-333.10.2337/diacare.29.02.06.dc05-170016443882
  25. Nakamura A, Shikata K, Hiramatsu M, Nakatou T, Kitamura T, Wada J, Itoshima T, Makino H. Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Care. 2005; 28(12): 2890-2895.10.2337/diacare.28.12.289016306550
  26. Troseid M, Seljeflot I, Hjerkinn EM, Arnesen H. Interleukin-18 is a strong predictor of cardiovascular events in elderly men with the metabolic syndrome: synergistic effect of inflammation and hyperglycemia. Diabetes Care. 2009; 32(3): 486-492.10.2337/dc08-1710264603419092166
  27. Thorand B, Kolb H, Baumert J, Koenig W, Chambless L, Meisinger C, Illig T, Martin S, Herder C. Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA/KORA Augsburg Study, 1984-2002. Diabetes. 2005; 54(10): 2932-2938.10.2337/diabetes.54.10.293216186395
  28. Tenger C, Sundborger A, Jawien J, Zhou X. IL-18 accelerates atherosclerosis accompanied by elevation of IFN-gamma and CXCL16 expression independently of T cells. Arterioscler Thromb Vasc Biol. 2005; 25(4): 791-796.10.1161/01.ATV.0000153516.02782.6515604417
  29. Rosso R, Roth A, Herz I, Miller H, Keren G, George J. Serum levels of interleukin-18 in patients with stable and unstable angina pectoris. Int J Cardiol. 2005; 98(1): 45-48.10.1016/j.ijcard.2003.08.02015676165
  30. Hulthe J, McPheat W, Samnegard A, Tornvall P, Hamsten A, Eriksson P. Plasma interleukin (IL)-18 concentrations is elevated in patients with previous myocardial infarction and related to severity of coronary atherosclerosis independently of C-reactive protein and IL-6. Atherosclerosis. 2006; 188(2): 450-454.10.1016/j.atherosclerosis.2005.11.01316405895
  31. Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, Rupprecht Interleukin 18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation. 2002; HJ. 106(1): 24-30.10.1161/01.CIR.0000020546.30940.9212093765
  32. Blankenberg S, Luc G, Ducimetière P, Arveiler D, Ferrières J, Amouyel P, Evans A, Cambien F, Tiret L, on behalf of the PRIME Study Group. Interleukin-18 and the risk of coronary heart disease in European men: The Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation. 2003; 108(20): 2453-2459.10.1161/01.CIR.0000099509.76044.A214581397
  33. Arimitsu J, Hirano T, Higa S, Kawai M, Naka T, Ogata A, Shima Y, Fujimoto M, Yamadori T, Hagiwara K, Ohgawara T, Kuwabara Y, Kawase I, Tanaka T. IL-18 gene polymorphisms affect IL-18 production capability by monocytes. Biochem Biophys Res Commun. 2006; 342(4): 1413-1416.10.1016/j.bbrc.2006.02.09616516851
  34. Hernesniemi JA, Karhunen PJ, Oksala N, Kähönen M, Levula M, Rontu R, Ilveskoski E, Kajander O, Goebeler S, Viiri LE, Hurme M, Lehtimäki T. Interleukin 18 gene promoter polymorphism: a link between hypertension and pre-hospital sudden cardiac death: the Helsinki Sudden Death Study. Eur Heart J. 2009; 30(23): 2939-2946.10.1093/eurheartj/ehp31619687159
  35. Kathiresan S, Newton-Cheh C, Gerszten RE. On the interpretation of genetic association studies. Eur Heart J. 2004; 25(16): 1378-1381.10.1016/j.ehj.2004.06.03515321696
Language: English
Page range: 3 - 9
Published on: Jul 25, 2011
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year

© 2011 S Kariž, D Petrovič, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons License.

Volume 14 (2011): Issue 1 (June 2011)